Skip to main content


Page 12 of 17

  1. The Editors of Thrombosis Journal would like to thank all of our reviewers who have contributed to the journal in Volume 13 (2015) and whose valuable support is fundamental to its success.

    Authors: Hugo ten Cate and Yukio Ozaki
    Citation: Thrombosis Journal 2016 14:5
  2. Data estimating the annual incidence of venous thromboembolism (VTE) in France, taking into account both hospital and community settings, are very lacking.

    Authors: Stéphane Bouée, Corinne Emery, Adeline Samson, Julie Gourmelen, Cécile Bailly and François-Emery Cotté
    Citation: Thrombosis Journal 2016 14:4
  3. Despite the association of cancer-derived circulating tissue factor (TF)-containing microvesicles and hypercoagulable state, correlations with the incidence of thrombosis remain unclear.

    Authors: Camille Ettelaie, Mary EW Collier, Sophie Featherby, Naima E. Benelhaj, John Greenman and Anthony Maraveyas
    Citation: Thrombosis Journal 2016 14:2
  4. Thus far, validated whole blood assays used in in vitro fibrinolysis experiments using thromboelastometry (ROTEM) are lacking or have yet to be tested in humans.

    Authors: Gerhardus J. A. J. M. Kuiper, Marie-Claire F. Kleinegris, René van Oerle, Henri M. H. Spronk, Marcus D. Lancé, Hugo ten Cate and Yvonne M. C. Henskens
    Citation: Thrombosis Journal 2016 14:1
  5. The aim of the study was to discuss the results of catheter-directed thrombolysis and complementary procedures to treat acute iliofemoral deep vein thrombosis (DVT) evaluating the safety and effectivness of an...

    Authors: Leslie Fiengo, Federico Bucci, Elias Khalil and Bruno Salvati
    Citation: Thrombosis Journal 2015 13:40
  6. Dabigatran is an alternative to warfarin (WF) for the thromboprophylaxis of stroke in patients with non-valvular atrial fibrillation (NVAF). The advantage of dabigatran over WF is that monitoring is not requir...

    Authors: Kazunori Otsui, Diana A. Gorog, Junichiro Yamamoto, Takayuki Yoshioka, Sachiyo Iwata, Atsushi Suzuki, Toru Ozawa, Asumi Takei and Nobutaka Inoue
    Citation: Thrombosis Journal 2015 13:39
  7. Although aspirin has a well-established role in preventing adverse events in patients with known cardiovascular disease (CVD), its benefit in patients without a history of CVD remains under scrutiny. Current d...

    Authors: Jobert Richie N. Nansseu and Jean Jacques N. Noubiap
    Citation: Thrombosis Journal 2015 13:38
  8. The aim of this study was to assess the safety and efficacy of switching therapy from low molecular weight heparin (LMWH; enoxaparin) to dabigatran for prevention of venous thromboembolic events (VTE) in patie...

    Authors: Christian Wurnig, Andreas Clemens, Helmuth Rauscher, Eva Kleine, Martin Feuring, Reinhard Windhager and Josef Grohs
    Citation: Thrombosis Journal 2015 13:37
  9. Two phase 3 trials compared 28–35 days of treatment with oral dabigatran 220 mg or 150 mg (RE-NOVATE) or 220 mg (RE-NOVATE II) once daily with subcutaneous enoxaparin 40 mg once daily for prevention of venous ...

    Authors: Bengt I. Eriksson, Ola E. Dahl, Nadia Rosencher, Andreas Clemens, Stefan Hantel, Martin Feuring, Jörg Kreuzer, Michael Huo and Richard J. Friedman
    Citation: Thrombosis Journal 2015 13:36
  10. Venous thromboembolism (VTE) could be manifested as deep venous thrombosis (DVT) or pulmonary embolism (PE). DVT is usually the more common manifestation and is usually formation of a thrombus in the deep vein...

    Authors: Soudabeh Hosseini, Ebrahim Kalantar, Maryam Sadat Hosseini, Shadi Tabibian, Morteza Shamsizadeh and Akbar Dorgalaleh
    Citation: Thrombosis Journal 2015 13:35
  11. Venous thromboembolism (VTE) is a major health problem, with over one million events every year in Europe. However, there is a paucity of data on the current management in real life, including factors influenc...

    Authors: Giancarlo Agnelli, Anselm K. Gitt, Rupert Bauersachs, Eva-Maria Fronk, Petra Laeis, Patrick Mismetti, Manuel Monreal, Stefan N. Willich, Wolf-Peter Wolf and Alexander T. Cohen
    Citation: Thrombosis Journal 2015 13:41
  12. The aim was to assess the risk of venous thromboembolism (VTE) associated with use of combined oral contraceptives (COCs) in women with a family history of VTE.

    Authors: Bengt Zöller, Henrik Ohlsson, Jan Sundquist and Kristina Sundquist
    Citation: Thrombosis Journal 2015 13:34
  13. Deep vein thrombosis (DVT) and pulmonary emboli (PE), known together as venous thromboembolic (VTE) disease remain major complications following elective hip and knee surgery. This study compares three chemopr...

    Authors: Murray M. Bern, Diane Hazel, Elizabeth Deeran, John R. Richmond, Daniel M. Ward, Damon J. Spitz, David A. Mattingly, James V. Bono, Ronna H. Berezin, Laura Hou, Gerald B. Miley and Benjamin E. Bierbaum
    Citation: Thrombosis Journal 2015 13:32
  14. Platelet activation, thrombin generation and fibrin formation play important roles in intracoronary thrombus formation, which may lead to acute myocardial infarction.

    Authors: C. H. Hansen, V. Ritschel, S. Halvorsen, G. Ø. Andersen, R. Bjørnerheim, J. Eritsland, H. Arnesen and I. Seljeflot
    Citation: Thrombosis Journal 2015 13:31
  15. We report a case of unsuccessful percutaneous mechanical thrombectomy in treatment of a high-risk pulmonary embolism (PE). Pulmonary thromboemboli are commonly expected as a homogenous mass, rich with red bloo...

    Authors: Jernej Vidmar, Igor Serša, Eduard Kralj and Peter Popovič
    Citation: Thrombosis Journal 2015 13:30
  16. Dual antiplatelet therapy based on the combination of an adenosine diphosphate (ADP)-receptor antagonist plus aspirin has demonstrated to be more effective in reducing the rate of major ischemic vascular event...

    Authors: Hernan Polo Friz, Mauro Molteni and Claudio Cimminiello
    Citation: Thrombosis Journal 2015 13:28
  17. Atrial fibrillation (AF) puts patients at risk of complications, including stroke. Warfarin therapy has been the mainstay of antithrombotic treatment for reducing the risk of stroke in AF. However, warfarin ha...

    Authors: Alpesh Amin and Steven Deitelzweig
    Citation: Thrombosis Journal 2015 13:29
  18. In the absence of thromboprophylaxis, patients undergoing total hip arthroplasty (THA) are at increased risk for venous thromboembolism (VTE). The objective of this study was to compare the efficacy and safety...

    Authors: Takeshi Fuji, Satoru Fujita, Yohko Kawai, Mashio Nakamura, Tetsuya Kimura, Masayuki Fukuzawa, Kenji Abe and Shintaro Tachibana
    Citation: Thrombosis Journal 2015 13:27
  19. Although quantitative anti-FXa assays can be used to measure rivaroxaban plasma levels, they are not widely performed or available. We aimed to tentatively determine the cut-off for thromboembolism and bleedin...

    Authors: Raul Altman and Claudio Daniel Gonzalez
    Citation: Thrombosis Journal 2015 13:26
  20. A 43-year-old woman recipient of a bare metal coronary stent during an acute anterior myocardial infarction was repeatedly hospitalized with recurrent stent thrombosis (ST) over the following 3 years. Emergent...

    Authors: Takao Konishi, Tadashi Yamamoto, Naohiro Funayama, Beni Yamaguchi, Seiichiro Sakurai, Hiroshi Nishihara, Koko Yamazaki, Yusuke Kashiwagi, Yasuki Sasa, Mitsuru Gima, Hideichi Tanaka, Daisuke Hotta and Kenjiro Kikuchi
    Citation: Thrombosis Journal 2015 13:25
  21. Plasma phospholipid transfer protein (PLTP) transfers lipids between donors and acceptors (e.g., from HDL to VLDL) and modulates lipoprotein composition, size, and levels. No study has reported an assessment of t...

    Authors: Hiroshi Deguchi, Gertrud Wolfbauer, Marian C. Cheung, Yajnavalka Banerjee, Darlene J. Elias, José A. Fernández, John J. Albers and John H. Griffin
    Citation: Thrombosis Journal 2015 13:24
  22. The introduction of central venous catheters has advanced medical care, particularly in hemato-oncology. However these can be associated with an increased thrombotic risk. Previous studies have compared the ra...

    Authors: Priya Sriskandarajah, Katharine Webb, David Chisholm, Ravi Raobaikady, Kim Davis, Natalie Pepper, Mark E Ethell, Mike N Potter and Bronwen E Shaw
    Citation: Thrombosis Journal 2015 13:21
  23. Venous thromboembolism (VTE) is a burden on healthcare systems. Standard treatment involves parenteral anticoagulation overlapping with a vitamin K antagonist, an approach that is effective but associated with...

    Authors: Luke Bamber, Dominic Muston, Euan McLeod, Anne Guillermin, Julia Lowin and Raj Patel
    Citation: Thrombosis Journal 2015 13:20
  24. The clinical picture of deep vein thrombosis (DVT) is nonspecific. Therefore assessment of the probability of occurrence of DVT plays a very important part in making a correct diagnosis of DVT.

    Authors: Małgorzata Dybowska, Witold Z Tomkowski, Paweł Kuca, Rafał Ubysz, Adam Jóźwik and Dariusz Chmielewski
    Citation: Thrombosis Journal 2015 13:18
  25. Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for the prevention and treatment of venous thromboembolism and for stroke prevention in patients with atrial fibrillation. NOACs do no...

    Authors: Hein Heidbuchel, Dana Berti, Manuel Campos, Lien Desteghe, Ana Parente Freixo, António Robalo Nunes, Vanessa Roldán, Vincenzo Toschi and Riitta Lassila
    Citation: Thrombosis Journal 2015 13:22
  26. Autoinflammatory diseases are a group of disorders due to acquired or hereditary disfunction of innate immune system and characterized by systemic or localized manifestations. The prototype is Familial Mediter...

    Authors: Micaela La Regina, Francesco Orlandini and Raffaele Manna
    Citation: Thrombosis Journal 2015 13:19
  27. The contact system, also named as plasma kallikrein-kinin system, consists of three serine proteinases: coagulation factors XII (FXII) and XI (FXI), and plasma prekallikrein (PK), and the nonenzymatic cofactor...

    Authors: Yi Wu
    Citation: Thrombosis Journal 2015 13:17
  28. Systemic Lupus Erythematosus (SLE) is an acquired, multiorgan, autoimmune disease. Clinical presentation is extremely variable and heterogeneous. It has been shown that SLE itself is an independent risk factor...

    Authors: Mario Bazzan, Antonella Vaccarino and Fabio Marletto
    Citation: Thrombosis Journal 2015 13:16
  29. In recent years, the relationship between inflammation and thrombosis has been deeply investigated and it is now clear that immune and coagulation systems are functionally interconnected.

    Authors: Giacomo Emmi, Elena Silvestri, Danilo Squatrito, Amedeo Amedei, Elena Niccolai, Mario Milco D’Elios, Chiara Della Bella, Alessia Grassi, Matteo Becatti, Claudia Fiorillo, Lorenzo Emmi, Augusto Vaglio and Domenico Prisco
    Citation: Thrombosis Journal 2015 13:15
  30. Inflammatory bowel disease affects more than 2 million people in Europe, with almost 20% of patients being diagnosed in pediatric age. Patients with inflammatory bowel disease are at increased risk of thromboe...

    Authors: Martina Giannotta, Gherardo Tapete, Giacomo Emmi, Elena Silvestri and Monica Milla
    Citation: Thrombosis Journal 2015 13:14
  31. Deep vein thrombosis (DVT) is a common disease and is associated with pulmonary embolism (PE). Proximal iliofemoral DVT may lead to severe PE and chronic venous insufficiency. The standard therapy for DVT is a...

    Authors: Norimichi Koitabashi, Nogiku Niwamae, Tetsuya Taguchi, Yoshiaki Ohyama, Noriaki Takama and Masahiko Kurabayashi
    Citation: Thrombosis Journal 2015 13:13
  32. Obesity is currently regarded as a pro-inflammatory condition during which leptin (Ob gene product) might act as a risk factor for Cardiovascular Diseases (CVD) including Acute Myocardial Infarction (AMI). There ...

    Authors: Devarajan Nalini, Rajendran Karthick, Vijay Shirin, Ganesan Manohar and Raghunathan Malathi
    Citation: Thrombosis Journal 2015 13:12
  33. The Editors of Thrombosis Journal would like to thank all of our reviewers who have contributed to the journal in Volume 12 (2014) and whose valuable support is fundamental to its success.

    Authors: Yukio Ozaki and Hugo ten Cate
    Citation: Thrombosis Journal 2015 13:11
  34. Current clinical practice guidelines recommend the use of prophylactic doses of low molecular weight heparins for cancer patients requiring hospitalization for acute medical illness. However, a recently publis...

    Authors: Patricia Moretto, Junghyun Park, Marc Rodger, Grégoire Le Gal and Marc Carrier
    Citation: Thrombosis Journal 2015 13:10
  35. Coagulation tests range from global or overall tests to assays specific to individual clotting factors and their inhibitors. Whether a particular test is influenced by an oral anticoagulant depends on the prin...

    Authors: Herm Jan M Brinkman
    Citation: Thrombosis Journal 2015 13:9
  36. Behçet’s disease (BD) is a rare vasculitis in sub-Saharan Africa. Vascular thrombosis, especially venous, is common in this condition and also constitutes a basic diagnostic criterion. Its affection of the sup...

    Authors: Simon Antoine Sarr, Pape Diadie Fall, Mouhamadou Chérif Mboup, Khadidiatou Dia, Malick Bodian and Modou Jobe
    Citation: Thrombosis Journal 2015 13:7
  37. Edoxaban is an oral, direct, factor Xa inhibitor approved in Japan for thromboembolic prophylaxis after lower-limb orthopedic surgery (LLOS), but contraindicated in patients with severe renal impairment (SRI; ...

    Authors: Takeshi Fuji, Satoru Fujita, Yohko Kawai, Yasuyuki Abe, Tetsuya Kimura, Masayuki Fukuzawa, Kenji Abe and Shintaro Tachibana
    Citation: Thrombosis Journal 2015 13:6
  38. Ideal conditions for platelet reactivity testing are critical for optimal selection of a P2Y12 inhibitor. Data are inconsistent regarding the impact of high-fat meals on test assessment.

    Authors: Paul P Dobesh, Jamela F Urban, Scott W Shurmur and Julie H Oestreich
    Citation: Thrombosis Journal 2015 13:3
  39. The global EINSTEIN DVT and PE studies compared rivaroxaban (15 mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K antagonist therapy and demonstrated non-inferiority for effica...

    Authors: Norikazu Yamada, Atsushi Hirayama, Hideaki Maeda, Satoru Sakagami, Hiroo Shikata, Martin H Prins, Anthonie WA Lensing, Masaharu Kato, Junichi Onuma, Yuki Miyamoto, Kazuma Iekushi and Mariko Kajikawa
    Citation: Thrombosis Journal 2015 13:2

    The Erratum to this article has been published in Thrombosis Journal 2016 14:11

  40. Homocysteine is an amino acid that is toxic to vascular endothelial cells, and plasma elevations have been associated with venous thromboembolism. Severe hyperhomocysteinemia (>100 μmol/L) may result from muta...

    Authors: Zuhier Awan, Sumayah Aljenedil, David S Rosenblatt, Jean Cusson, Brian M Gilfix and Jacques Genest
    Citation: Thrombosis Journal 2014 12:30
  41. Mild therapeutic hypothermia is considered standard care in the treatment of patients resuscitated from cardiac arrest. With increasingly more frequent concomitant use of platelet-inhibiting drugs, clinicians ...

    Authors: Sven Van Poucke, Kris Stevens, Abraham Emanuel Marcus and Marcus Lancé
    Citation: Thrombosis Journal 2014 12:31
  42. In clinical trials new oral anticoagulants (NOAC) have proved to be as effective as warfarin for thromboprophylaxis in atrial fibrillation. The aim of this study was to evaluate the efficacy and safety of thes...

    Authors: Ashkan Labaf, Martin Carlwe and Peter J Svensson
    Citation: Thrombosis Journal 2014 12:29

Official journal of

  • Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 2.6
    5-year Journal Impact Factor: 3.1
    Source Normalized Impact per Paper (SNIP): 0.653
    SCImago Journal Rank (SJR): 0.572

    Speed 2023
    Submission to first editorial decision (median days): 11
    Submission to acceptance (median days): 107

    Usage 2023
    Downloads: 708,004
    Altmetric mentions: 943